Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic drugs.
Full story here.
(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
